RESUMEN
BACKGROUND: The use of endoscopic submucosal dissection (ESD) is gradually expanding for treatment of neoplasia in Barrett's esophagus (BE). We aimed to report outcomes of all ESDs for BE neoplasia performed in the Netherlands. METHODS: Retrospective assessment of outcomes, using treatment and follow-up data from a joint database. RESULTS: 130/138 patients had complete ESDs, with 126/130 (97â%) en bloc resections. Median (interquartile range (IQR)) procedure time was 121 minutes (90-180). Pathology findings were high grade dysplasia (HGD) (5â%) or esophageal adenocarcinoma (EAC) T1a (43â%) or T1b (52â%; 19â% sm1, 33â%â≥âsm2). Among resections of HGD or T1a EAC lesions, 87â% (95â%CI 75â%-92â%) were both en bloc and R0; the corresponding value for T1b EAC lesions was 49â% (36â%-60â%). Among R1 resections, 10/34 (29â%) showed residual cancer, all detected at first endoscopic follow-up.âThe remaining 24 patients (71â%) showed no residual neoplasia. Six of these patients underwent surgery with no residual tumor; the remaining 18 underwent endoscopic follow-up during median 31 months with 1 local recurrence (annual recurrence rate 2â%). Among R0 resections, annual local recurrence rate during median 27 months was 0.5â%. CONCLUSION: In expert hands, ESD allows safe removal of bulky intraluminal neoplasia and submucosal cancer. ESD of the latter showed R1 resection margins in 50â%, yet only one third had persisting neoplasia at follow-up.âTo better stratify R1 patients with an indication for additional surgery, repeat endoscopy after healing of the ESD might be a helpful possible prognostic factor for residual cancer.
Asunto(s)
Esófago de Barrett , Resección Endoscópica de la Mucosa , Neoplasias Esofágicas , Adenocarcinoma , Esófago de Barrett/patología , Esófago de Barrett/cirugía , Resección Endoscópica de la Mucosa/métodos , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/cirugía , Humanos , Neoplasia Residual , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: Endoscopic cryoablation for Barrett's esophagus (BE) might offer advantages over heat-based ablation. Focal cryoballoon ablation has been promising for short-segment BE, whereas the novel 90°-swipe cryoballoon ablation system (CbSAS90) ablates larger areas in a single step (90° over 3âcm). The system allows for dose adjustment. CbSAS90 has been feasible and safe in animal and pre-esophagectomy studies. This is the first clinical study to assess feasibility, safety, and efficacy of CbSAS90 for eradication of dysplastic BE. METHODS: In this prospective study in dysplastic BE patients, dose finding started with semi-circumferential treatment at 0.8âmm/s (dose 1). The dose was escalated by reducing speed by 0.1âmm/s in six patients until BE surface regression was ≥â80â% without complications ("effective dose"). The effective dose was subsequently confirmed with circumferential treatment in 12 new patients. Post-procedural pain (0â-â10) and dysphagia (0â-â4) were evaluated. Outcomes were feasibility, safety, and BE surface regression. RESULTS: 25 patients were included, with technically successful treatment in 92â% (95â%CI 73â%â-â99â%). Median (95â%CI) BE surface regression was 78â% (50â%â-â85â%) for dose 1 and 85â% (55â%â-â95â%) for dose 2 (0.7âmm/s), which was defined as the effective dose. Circumferential treatment resulted in 93â% (88â%â-â96â%) regression. Two of 12 patients with circumferential treatment developed strictures that required dilation. Median pain and dysphagia scores were low (0â-â3 and 0, respectively). CONCLUSIONS: CbSAS90 was feasible and effective for ablating larger BE areas. The optimal dose for circumferential treatment that balances safety and efficacy requires further evaluation.
Asunto(s)
Esófago de Barrett , Ablación por Catéter , Criocirugía , Neoplasias Esofágicas , Animales , Esófago de Barrett/cirugía , Criocirugía/efectos adversos , Neoplasias Esofágicas/cirugía , Esofagoscopía , Estudios de Factibilidad , Humanos , Hiperplasia , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND AND AIMS: Endoscopic resection is the cornerstone of treatment of Barrett's esophagus (BE)-related neoplasia. However, accurate histopathologic evaluation of endoscopic resection specimens can be challenging, and the preferred specimen handling method remains unknown. Therefore, the aim of our study was to compare 3 different specimen handling methods for assessment of all clinically relevant histopathologic parameters and time required for specimen handling. METHODS: In this multicenter, randomized study EMR specimens of BE-related neoplasia with no suspicion of submucosal invasion during endoscopy were randomized to 3 specimen handling methods: pinning on paraffin using needles, direct fixation in formalin without prior tissue handling, and the cassette technique (small box for enclosing specimens). The histopathologic evaluation scores were assessed by 2 dedicated GI pathologists blinded to the handling method. RESULTS: Of the 126 randomized EMR specimens, 45 were assigned to pinning on paraffin, 41 to direct fixation in formalin, and 40 to the cassette technique. The percentages of specimens with overall optimal histopathologic evaluation scores were similar for the pinning method (98%; 95% confidence interval [CI], 88.0-99.9) and for no handling (90%; 95% CI, 76.9-97.3) but were significantly lower (64%; 95% CI, 47.2-78.8) for the cassette technique (P < .001). Time required for specimen handling was shortest when no handling method was used (P < .001 vs pinning and cassette). CONCLUSIONS: Both pinning on paraffin and direct fixation in formalin resulted in optimal histopathologic evaluation scores in a high proportion of specimens, whereas the cassette technique performs significantly worse, and its use in clinical daily practice should be discouraged. Given the significantly shorter handling time, direct fixation in formalin appears to be the preferred method over pinning on paraffin. However, the latter needs to be confirmed in larger studies with inclusion of all EMR specimens. (Clinical trial registration number: ISRCTN50525266.).